This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Johnson & Johnson (NYSE: JNJ) announced on Wednesday that it expects to begin a phase 1/2a clinical trial of its COVID-19 vaccine candidate Ad26.COV2-S, recombinant, in the second half of July. The company previously projected that the early-stage clinical study would begin in September.
In February, Johnson & Johnson established a partnership with BARDA (the Biomedical Advanced Research and Development Authority) to develop a COVID-19 vaccine candidate at an accelerated pace. Chief Scientific Officer Paul Stoffels noted that the strong preclinical data observed thus far and the company’s discussions with regulatory authorities were key in allowing it to speed up the development program.
The early-stage clinical trial will be conducted in the U.S. and in Belgium. Johnson & Johnson plans to enroll 1,045 healthy adults between the ages of 18 to 55, plus adults aged 65 and over.
Johnson & Johnson is also talking with the National Institutes of Allergy and Infectious Diseases about the possibility of starting a phase 3 study of its COVID-19 vaccine sooner if the early-stage studies produce positive results. The healthcare giant is ramping up manufacturing capacity for the experimental vaccine even before clinical testing is completed, with a goal of being able to supply over 1 billion doses next year if the vaccine proves safe and effective.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
3 "Double Down" Stocks To Ride The Bull Market
Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.
He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.
*Extreme Opportunities returns as of June 5th 2020
More reading
- Why the Keytone Dairy share price opened 9% higher this morning
- 3 great shares to buy now if you’re an ASX 200 investor in your 20s
- Why the Kogan share price jumped 11% to a record high today
- JB Hi-Fi share price higher after upgrading profit guidance for FY 2020
- Why do I own this ASX 200 share?
Keith Speights has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips
The post Johnson & Johnson to Begin Coronavirus Vaccine Clinical Trial in July appeared first on Motley Fool Australia.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
from Motley Fool Australia https://ift.tt/2UzF06t
Leave a Reply